ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "African-Americans"

  • Abstract Number: 226 • 2017 ACR/ARHP Annual Meeting

    Biopsy Proven Giant Cell Arteritis in African Descent Populations: Incidence and Characteristics in Martinique, French West Indies

    Florence Moinet1, Vincent Molinie2, Katlyne Polomat1, Harold Merle3, Marie Blettery4, Lauren Brunier-Agot4, Michel DeBandt4 and Christophe Deligny1, 1Internal medicine, National referral Center for Lupus, Antiphospholipid syndrome and other rare auto-immune diseases, Hopital Pierre Zobda Quitman, CHU de Martinique, Fort de France, Martinique, 2Pathology unit, Hopital Pierre Zobda Quitman, CHU de Martinique, Fort de France, Martinique, 3Ophthalmology, Hopital Pierre Zobda Quitman, CHU de Martinique, Fort de France, Martinique, 4Rheumatology, Hopital Pierre Zobda Quitman, CHU de Martinique, Fort de France, Martinique

    Background/Purpose: Multiple epidemiological studies ascertained that GCA is one of the most common systemic vasculitis in western countries. But, there is only one study based…
  • Abstract Number: 689 • 2017 ACR/ARHP Annual Meeting

    Apolipoprotein L1 Risk Variants Associate with Hypertension and Nephritis Progression Despite Lower dsDNA Titers in Ghanaian Systemic Lupus Erythematous Patients

    Ashira Blazer1, Ida Dzifa Dey2, Sara Rasmussen3, Robert M. Clancy4 and Jill P. Buyon5, 1Internal Medicine Division of Rheumatology, NYU School of Medicine, New York, NY, 2Internal Medicine, Rheumatology, The University of Ghana, Accra, Ghana, 3Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, 4NYU School of Medicine, New York, NY, 5Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose: Two Apolipoprotein L1 (APOL1) risk variants (RV), G1 and G2 are enriched in African populations due to a conferred resistance to Trypanosoma brucei. This…
  • Abstract Number: 915 • 2017 ACR/ARHP Annual Meeting

    Pesticide Exposure and Risk of Systemic Lupus Erythematosus in an Urban Population of Predominantly African-American Women

    Jessica Williams1, Shun-Chiao Chang1, Corine Sinnette1, Susan Malspeis2, Christine G. Parks3, Elizabeth Karlson1, Patricia Fraser1 and Karen H. Costenbader1, 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Epidemiology Branch, National Institute of Environmental Health Sciences, NIH, Durham, NC

    Background/Purpose: Several studies have reported an association between exposure to pesticides and the risk of systemic lupus erythematosus (SLE). However, this association has not yet…
  • Abstract Number: 919 • 2017 ACR/ARHP Annual Meeting

    HLA Type Imputation in the Genome Research in African American Scleroderma Patients (GRASP) Cohort Reveals Strong Associations of African Ancestry MHC Class II Types with Scleroderma and Lack of Class I HLA Type Associations

    Elaine F. Remmers1, Pravitt Gourh2, Steven Boyden3, Nadia D. Morgan4, Ami A. Shah4, Adebowale Adeyemo1, Amy Bentley1, Mary A. Carns5, Settara C. Chandrasekharappa1, Lorinda Chung6, Lindsey A. Criswell7, Chris T. Derk8, Robyn T. Domsic9, Ayo Doumatey1, Heather Gladue10, Avram Goldberg11, Jessica K. Gordon12, Vivien M Hsu13, Reem Jan14, Dinesh Khanna15, Maureen D. Mayes16, Thomas A. Medsger Jr.17, Paula S. Ramos18, Marcin A. Trojanowski19, Lesley A. Saketkoo20, Elena Schiopu15, Victoria K. Shanmugam21, Daniel Shriner1, Richard M. Silver22, Virginia D. Steen23, Antonia Valenzuela24, John Varga25, Charles Rotimi1, Fredrick M. Wigley26, Francesco Boin27 and Daniel L. Kastner28, 1National Institutes of Health (NIH), National Human Genome Research Institute, Bethesda, MD, 2NIAMS-Rheumatology, National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 3National Institutes of Health (NIH), National Institute on Deafness and Other Communication Disorders, Bethesda, MD, 4Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 5Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, 6Rheumatology, Stanford University Medical Center, Palo Alto, CA, 7Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 8Rheumatology, University of Pennsylvania, Philadelphia, PA, 9Rheumatology, University of Pittsburgh, Pittsburgh, PA, 10Rheumatology, Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, 11NYU Langone Medical Center, New York, NY, 12Rheumatology, Hospital for Special Surgery, New York, NY, 13University of Medicine and Dentistry of New Jersey--Robert Wood Johnson Medical School, New Brunswick, NJ, 14Medicine, Rheumatology, University of Chicago, Chicago, IL, 15University of Michigan, Ann Arbor, MI, 16University of Texas McGovern Medical School, Houston, TX, 17Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, 18Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, 19Boston University School of Medicine, Boston, MA, 20Rheumatology, Tulane University School of Medicine, New Orleans, LA, 21Rheumatology, The George Washington University, Washington, DC, 22Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, 23Rheumatology, MedStar Georgetown University Hospital, Washington, DC, 24Stanford University School of Medicine, Stanford, CA, 25Rheumatology and Dermatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, 26Rheum Div/Mason F Lord, Johns Hopkins University, Baltimore, MD, 27Rheumatology, University California, San Francisco, San Francisco, CA, 28Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

    Background/Purpose: The Genome Research in African American Scleroderma Patients (GRASP) consortium was created to obtain a collection of African American (AA) scleroderma patients to facilitate…
  • Abstract Number: 1018 • 2017 ACR/ARHP Annual Meeting

    Comprehensive Identification of Differentially Methylated Regions Associated with Systemic Sclerosis in Dermal Fibroblasts from African-American Patients

    Paula S. Ramos1,2, Willian da Silveira3, E. Starr Hazard3, Ilia Atanelishvili4, Robert C. Wilson5, Jim C. Oates1, Galina S. Bogatkevich4 and Gary Hardiman1,2,3, 1Department of Medicine, Medical University of South Carolina, Charleston, SC, 2Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, 3Center for Genomic Medicine, Medical University of South Carolina, Charleston, SC, 4Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, 5Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC

    Background/Purpose: The etiology and reasons underlying the ethnic disparities in systemic sclerosis (SSc) remain unknown. African-Americans are disproportionally affected by SSc, yet dramatically underrepresented in…
  • Abstract Number: 1697 • 2017 ACR/ARHP Annual Meeting

    Unique Characteristics of Scleroderma Among African Americans: A Population Based Study

    Sarah M. Compton1, Richard M. Silver2 and Diane L. Kamen3, 1Internal Medicine, Medical University Of South Carolina, Charleston, SC, 2Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, 3Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease categorized on the basis of skin involvement as either limited or diffuse cutaneous SSc, the latter…
  • Abstract Number: 2161 • 2017 ACR/ARHP Annual Meeting

    Comparison of Clinical Characteristics between African American and Caucasian Patients with Polymyositis and Dermatomyositis and Their Response to Conventional Treatment

    Heena Birbal Jain1, Vladimir Liarski2, Kichul Ko3,4,5 and Anisha Dua5,6, 1Rheumatology, University of Chicago, Chicago, IL, 2Rheumatology - Internal Medicine, University of Chicago, Chicago, IL, 3Medicine, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, 4Rheumatology and Knapp Center for Lupus Research, University of Chicago, Chicago, IL, 5Medicine, University of Chicago, Chicago, IL, 6Section of rheumatology, University of Chicago, chicago, IL

    Background/Purpose:  Prior studies have shown that increased age at diagnosis and non-Caucasian race are associated with lower survival in polymyositis and dermatomyositis (PM/DM). However, itÕs…
  • Abstract Number: 2518 • 2017 ACR/ARHP Annual Meeting

    Racial Differences in Clinical Characteristics and Co-Morbidities of Ankylosing Spondylitis

    Dilpreet Singh1 and Marina N. Magrey2, 1Rheumatology, Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, OH, 2Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, OH

    Background/Purpose: Ethnic heterogeneity of the United States (US) population makes it imperative to study the racial differences in clinical characteristics of Ankylosing Spondylitis (AS) patients,…
  • Abstract Number: 2813 • 2017 ACR/ARHP Annual Meeting

    Interferon-Induced APOL1 over-Expression Causes Autophagic Dysfunction and Mitochondrial Stress in Risk Variant-Carrying Endothelial Cells

    Ashira Blazer1, Sara Rasmussen2, Androo Markham3, Shilpi Mehta-Lee4, Jill P. Buyon4 and Robert M. Clancy2, 1Division of Rheumatology, NYU School of Medicine, New York, NY, 2Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, 3Medicine, NYU School of Medicine, New York, NY, 4NYU School of Medicine, New York, NY

    Background/Purpose: In SLE Apolipoprotein L1 (APOL1) risk variants (RV) associate with cardiovascular and end stage renal disease. APOL1 induction initially promotes cellular maintenance through autophagy;…
  • Abstract Number: 2814 • 2017 ACR/ARHP Annual Meeting

    Interferon-β Production By B Cells Promotes B Cell Survival and Is Strongly Associated with Active Disease in African Americans with SLE

    Jennie Hamilton1, Qi Wu2, PingAr Yang3, Bao Luo4, Shanrun Liu5, Jun Li6, Ignacio Sanz7, W. Winn Chatham8, Hui-Chen Hsu2 and John D. Mountz9, 1Medicine/Division of Clinical Immunology and Rhematology, University of Alabama at Birmingham, Birmingham, AL, 2Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 3Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 5Biochemistry & Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, 6Medicine, University of Alabama at Birmingham, Birmingham, AL, 7Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA, 8Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 9University of Alabama at Birmingham, Department of Medicine, Birmingham, AL

    Background/Purpose: Plasmacytoid dendritic cells are considered the main source of pathogenic IFN in SLE. However, recent work found that elevated serum type I IFN protein…
  • Abstract Number: 2930 • 2017 ACR/ARHP Annual Meeting

    Transforming Growth Factor Beta 3 (TGFB3) – a Novel Systemic Sclerosis Susceptibility Locus Involved in Fibrosis and Th17 Cell Development Identified By Genome-Wide Association Study in African Americans from the Genome Research in African American Scleroderma Patients Consortium

    Pravitt Gourh1, Elaine F. Remmers2, Ansuman Satpathy3, Steven Boyden4, Nadia D. Morgan5, Ami A. Shah6, Adebowale Adeyemo2, Amy Bentley2, Mary A. Carns7, Settara C Chandrasekharappa2, Lorinda Chung8, Lindsey A. Criswell9, Chris T. Derk10, Robyn T. Domsic11, Ayo Doumatey2, Heather Gladue12, Avram Goldberg13, Jessica K. Gordon14, Vivien Hsu15, Reem Jan16, Dinesh Khanna17, Maureen D. Mayes18, Thomas A. Medsger Jr.19, Maxwell Mumbach3, Paula S. Ramos20, Marcin Trojanowski21, Lesley Ann Saketkoo22, Elena Schiopu17, Victoria K. Shanmugam23, Daniel Shriner2, Richard M. Silver24, Virginia D. Steen25, Antonia Valenzuela26, John Varga27, Howard Chang3, Charles Rotimi2, Fredrick M. Wigley28, Francesco Boin29 and Daniel L. Kastner30, 1NIAMS-Rheumatology, National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 2National Institutes of Health (NIH), National Human Genome Research Institute, Bethesda, MD, 3Stanford University, Stanford, CA, 4National Institutes of Health (NIH), National Institute on Deafness and Other Communication Disorders, Bethesda, MD, 5Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 6Division of Rheumatology, Johns Hopkins University, Baltimore, MD, 7Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, 8Rheumatology, Stanford University Medical Center, Palo Alto, CA, 9Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 10Rheumatology, University of Pennsylvania, Philadelphia, PA, 11Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 12Rheumatology, Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, 13NYU Langone Medical Center, New York, NY, 14Rheumatology, Hospital for Special Surgery, New York, NY, 15Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, 16Medicine, Rheumatology, University of Chicago, Chicago, IL, 17University of Michigan, Ann Arbor, MI, 18University of Texas McGovern Medical School, Houston, TX, 19Medicine/Rheumatology, Univ of Pittsburgh, Pittsburgh, PA, 20Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, 21Boston University, Boston, MA, 22Tulane, New Orleans, LA, 23Rheumatology, The George Washington University, Washington, DC, 24Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, 25Rheumatology, MedStar Georgetown University Hospital, Washington, DC, 26Stanford University School of Medicine, Stanford, CA, 27Rheumatology and Dermatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, 28Rheum Div/Mason F Lord, Johns Hopkins University, Baltimore, MD, 29Rheumatology, University California, San Francisco, San Francisco, CA, 30Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

    Background/Purpose: Systemic sclerosis (SSc) is a multisystem disease that has a higher prevalence in African Americans (AA), with a more severe phenotype, internal organ involvement,…
  • Abstract Number: 780 • 2016 ACR/ARHP Annual Meeting

    Belimumab Use in African-American Patients in an U.S. Academic Medical Center

    Paloma Alejandro1, Anjani Pillarisetty2 and Christopher E. Collins3, 1Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC, 2Internal Medicine, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC, 3MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC

    Background/Purpose: Belimumab is an anti-BAFF monoclonal antibody approved for the treatment of auto-antibody positive patients with SLE. In two large phase 3 clinical trials, belimumab…
  • Abstract Number: 1969 • 2016 ACR/ARHP Annual Meeting

    Peer Approaches to Lupus Self-Management (PALS): A Novel Lupus Peer Mentorship Intervention

    Edith M. Williams1, Leonard Egede2, Jim Oates3, Delia Voronca2 and Mulugeta Gebregziabher2, 1Public Health Sciences, Medical University of South Carolina, Charleston, SC, 2Medical University of South Carolina, Charleston, SC, 3Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that is associated with increased morbidity, mortality, health care costs and decreased quality of life.…
  • Abstract Number: 2351 • 2016 ACR/ARHP Annual Meeting

    Racial Differences in Magnetic Resonance Image-Based Three-Dimensional Bone Shape of the Knee: Data from the Osteoarthritis Initiative (OAI)

    Jing-Sheng Li1, Michael A Bowes2, David T. Felson3, Philip G. Conaghan4, Carrie Brown5 and Tuhina Neogi6, 1Boston University, Boston, MA, 2Imorphics Ltd, Manchester, United Kingdom, 3Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 5Boston University School of Public Health, Boston, MA, 6Clinical Epidemiology, Boston University School of Medicine, Boston, MA

    Background/Purpose:  African Americans have higher prevalence and greater severity of knee osteoarthritis (OA) on radiographs compared with Caucasians. Magnetic resonance imaging (MRI)-based quantification of 3-dimensional…
  • Abstract Number: 3103 • 2016 ACR/ARHP Annual Meeting

    Apolipoprotein L1 Risk Variants Associate with Prevalent Cardiovascular Disease in African American Systemic Lupus Erythematous Patients

    Ashira Blazer1, Robert M Clancy2, H. Michael Belmont3, Peter M. Izmirly3, Androo Markham4 and Jill P. Buyon4, 1Division of Rheumatology, NYU School of Medicine, New York, NY, 2Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 3New York University School of Medicine, New York, NY, 4Medicine, New York University School of Medicine, New York, NY

    Background/Purpose:  Two Apolipoprotein L1 (APOL1) risk variants (RV), G1 and G2, located on chromosome 22q12.3, have been associated with excess renal risk in African Americans…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology